You are here:
NICE
NICE Guidance
Conditions and diseases
Cancer
Colorectal cancer
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Technology appraisal guidance
Reference number:
TA212
Published:
15 December 2010
Guidance
Tools and resources
Information for the public
History
Download guidance (PDF)
Overview
1 Guidance
2 The technology
3 The manufacturer's submission
4 Consideration of the evidence
5 Implementation
6 Related NICE guidance
7 Review of guidance
Appendix A: Appraisal Committee members and NICE project team
Appendix B: Sources of evidence considered by the Committee
Changes after publication
About this guidance
Changes after publication
February 2014:
minor maintenance
March 2012:
minor maintenance
Next page
About this guidance
Previous page
Appendix B: Sources of evidence considered by the Committee